U.S. markets closed

InnoCan Pharma Corporation (IP4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.8550-0.1550 (-15.35%)
At close: 7:39PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0100
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.8000 - 1.0780
52 Week Range0.0860 - 1.3700
Avg. Volume193,842
Market Cap197.35M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

      Virtual Investor Conferences® and KCSA Strategic Communications today announced that the presentations from the September 8th & 9th Cannabis Industry Virtual lnvestor Conference are now available for on-demand viewing at VirtualInvestorConferences.com.

    • Newsfile

      Innocan Pharma's CBD-Loaded Liposome Platform Technology Demonstrates a Prolonged Release of CBD in Large Animals

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that it has conducted a recent experimental study of its CBD-loaded liposome technology (LPT) on large animals that demonstrated a similar pharmacokinetic profile as was demonstrated in a previous small animal study. This result is expected to bring the Company closer to clinical trials in humans.Pharma

    • CNW Group

      Cannabis Executives Present: Cannabis Investor Conference September 8th & 9th

      Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 11:30 AM ET on Wednesday, September 8th.